Israel - English - Ministry of Health

medison pharma ltd - odevixibat as sesquihydrate - hard capsule - odevixibat as sesquihydrate 1200 mcg - odevixibat - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or olderbylvay is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with alagille syndrome (algs).

Israel - English - Ministry of Health

medison pharma ltd - odevixibat as sesquihydrate - hard capsule - odevixibat as sesquihydrate 200 mcg - odevixibat - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or olderbylvay is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with alagille syndrome (algs).

Israel - English - Ministry of Health

medison pharma ltd - odevixibat as sesquihydrate - hard capsule - odevixibat as sesquihydrate 400 mcg - odevixibat - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or olderbylvay is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with alagille syndrome (algs).

Israel - English - Ministry of Health

medison pharma ltd - odevixibat as sesquihydrate - hard capsule - odevixibat as sesquihydrate 600 mcg - odevixibat - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or olderbylvay is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with alagille syndrome (algs).

European Union - English - EMA (European Medicines Agency)

albireo - odevixibat - cholestasis, intrahepatic - bile and liver therapy - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4.4 and 5.1).